News
Discovered and developed by Sarepta Therapeutics, Elevidys is a gene therapy that won accelerated approval in June 2023 and ...
1d
TipRanks on MSNFDA investigating death of child who received Sarepta’s ElevidysThe U.S. FDA is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta (SRPT) Therapeutics gene therapy for Duchenne ...
Roche is pausing shipments of Elevidys in some countries, following partner Sarepta Therapeutics’ move in the U.S., as safety ...
Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results